<DOC>
	<DOCNO>NCT02145884</DOCNO>
	<brief_summary>We plan conduct study , see safe effective timolol maleate 0.5 % gel-forming solution infantile hemangioma ( IH ) response hemangioma timolol maleate 0.5 % . Our hypothesis timolol inhibit possibly reverse growth appropriate infantile hemangioma .</brief_summary>
	<brief_title>Topical Timolol Gel Treatment Infantile Hemangiomas</brief_title>
	<detailed_description>Subjects assign open label timolol maleate 0.5 % . Parents instruct place 1 2 drop twice day center hemangioma . Subjects expect use study drug direct every day 4 month period . Subjects assess baseline , 2 week , 4 week , every 4 week thereafter total 5 month . Physical exam , photograph compare size color intensity , scale improvement complete visit . Parents complete quality life questionnaire regard child 's hemangioma impact quality life . Subjects evidence worsen would remove study transfer clinic evaluation treatment .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Written inform permission study participation use patient 's image obtain patient 's parent ( ) guardian ( ) , The patient 7 day 6 month age time enrollment , proliferate HOI require systemic therapy present anywhere body , Multiple hemangioma may treat child , hemangioma meet criterion . patient otherwise generally healthy ; risk imminent ulceration , lifethreatening , functionthreatening , ulcerate ; patient previously receive systemic , intralesional topical corticosteroid , imiquimod , vincristine , alphainterferon , propranolol beta blocker ; patient previously treat his/her HOI , include surgical and/or medical procedure ; patient whose mother breastfeed patient also treat betablockers , systemic corticosteroid , vincristine alphainterferon ; patient previously experience anaphylactic reaction ; patient unclear diagnosis HOI ; patient participate another clinical study live household infant already participate study ; patient bear prematurely yet reach his/her term equivalent age ; patient parent ( ) guardian ( ) contact telephone case emergency .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hemangioma</keyword>
	<keyword>birthmark</keyword>
	<keyword>strawberry hemangioma</keyword>
	<keyword>timolol</keyword>
</DOC>